Korea’s Prescription Monopoly Faces Its Data Reckoning

South Korea’s healthcare model, often praised for its digital efficiency, hides a structural paradox.

It knows everything yet changes little. The nation’s data-driven Drug Utilization Review (DUR) network records nearly every prescription in real time—antibiotics, corticosteroids, antihistamines—but it almost never intervenes. Less than seven percent of warnings lead to modification. Behind this inertia lies a legal architecture built on trust in one profession alone: physicians.

The current system is the legacy of the year 2000 medical reform known as uiyak bunup, or the separation of prescribing and dispensing. It was conceived to break financial ties between doctors and pharmaceutical suppliers, an ethical firewall that seemed progressive at the time. But it also granted physicians an exclusive right to prescribe, a monopoly that subsequent technology only digitized, not democratized. Pharmacists became legally independent but functionally subordinate; insurers could monitor but not question; and the government could collect data but rarely act. What was meant to protect autonomy matured into dependence—a hierarchy that survives through inertia and culture as much as through law.

In this vertically sealed ecosystem, discretion equals authority. Clinics sustain themselves through rapid symptom relief—often steroid injections or first-generation antihistamines that silence flare-ups but do not address chronic causes. Such prescriptions generate gratitude and return visits; they also anchor revenue. A 2023 BioMed Central study found that clinics with higher steroid prescribing rates faced significantly lower closure risk, suggesting that the market rewards immediacy over prudence. The state’s oversight mechanisms, designed to discourage excess, have instead normalized it. The more a clinic prescribes, the more it survives.

The costs are systemic. Korea ranks among the OECD’s highest in prescription volume per capita, especially for anti-inflammatory and psychotropic drugs. Generic substitution remains below 10 percent of outpatient cases, compared with 60–70 percent in most of Europe. Brand loyalty, institutionalized through the prescribing act itself, distorts prices and inflates insurance expenditures. Yet no one—not pharmacist, insurer, nor regulator—can alter a physician’s order without consent. The system performs oversight in name but not in power, an ecosystem of observation without intervention.

A System Built on Trust and Designed for Dependence

The reform’s logic was noble: separate financial interest from medical judgment. But the resulting compromise enshrined a professional monopoly. The Medical Service Act defined prescribing as an exclusive clinical act; the Pharmacy Act limited pharmacists to dispensing. The relationship between the two became sequential rather than collaborative—one decides, the other executes. When digital tools arrived in the 2010s, they were grafted onto this structure rather than used to reshape it. The DUR, the Patient Drug Monitoring (PDM) database, and the National Integrated Medical System (NIMS) created a wealth of data but no procedural right to act on it. Authority remained analog even as information went digital.

This separation of information from power is now the core dysfunction. Data show duplication, misuse, and over-treatment, yet the institutions that observe cannot intervene. Oversight is retrospective—audits months after the fact, not safeguards at the point of care. For patients who cycle between clinics seeking relief from recurring allergies or dermatitis, the system registers each steroid injection and antihistamine tablet but never recognizes the pattern as risk. It records symptoms without memory.

Accountability as System, Not Suspicion

Elsewhere, similar reforms evolved into shared-governance models. In Germany, the Aut-idem rule obliges pharmacists to substitute cheaper generics unless a physician explicitly forbids it; France applies substitution by default, requiring justification to override. Sweden’s digital registries update drug equivalence and pricing weekly, allowing automatic substitution within reimbursable categories. Japan’s regional electronic charts synchronize prescriber and dispenser data, while the United States uses Prescription Drug Monitoring Programs to detect overuse or doctor-shopping in real time. Across these systems, accountability is structural, not adversarial—an operational principle rather than a challenge to professional dignity.

Korea’s architecture differs not in capacity but in permission. It possesses one of the richest national health datasets in the world, yet the law treats that information as documentation, not decision. DUR alerts cannot block; substitution requires prior consent; and insurers must reimburse even questionable prescriptions until proven fraudulent. The result is what policy theorists call “transparency without traction.” Visibility expands, but responsibility does not.

This pattern reflects a deeper cultural equation: autonomy as the essence of professionalism. The fear that shared authority equals diminished expertise has stalled every attempt to re-balance the system. Yet other countries have shown that shared governance, when codified in law, strengthens rather than weakens trust. The distinction lies not in who decides, but in how decisions are verified.

From Autonomy to Shared Governance

That shift is now, cautiously, underway. Several bills before the National Assembly seek to convert observation into action. The Simplified Substitution Bill would permit pharmacists to dispense equivalent generics without prior approval, logging each change electronically. The Ingredient-Based Prescribing Bill would compel doctors to specify active compounds instead of brand names, curbing commercial bias. A proposed DUR Hard-Stop Amendment would transform current warnings into mandatory blocks for contraindicated or duplicate drugs. These are incremental changes, but together they redefine prescription not as a private transaction but as a public data event.

Implementing them will require harmonizing three conflicting laws: the Medical Service Act, the Pharmacy Act, and the Personal Information Protection Act. It will also challenge entrenched economic interests—pharmaceutical suppliers who depend on brand loyalty, and clinics whose revenue hinges on rapid symptom management. Critics warn of bureaucratization and data overreach; advocates see an overdue alignment between authority and accountability.

Beneath the policy details lies a moral recalibration. Every prescription, financed by national insurance, is a collective act that affects public cost and safety. Treating it as an inviolable private decision is increasingly untenable. As one Seoul health economist observed, “We have built a museum of medical data, but no curator.” The next reform will test whether Korea can transform that museum into a living system of governance.

The government’s 2026 plan for a National Prescription Observatory aims to integrate all prescribing data into a single, auditable network. Each order would become traceable across institutions, allowing pharmacists to flag inconsistencies and insurers to model risk dynamically. Doctors would retain diagnostic authority, but within a transparent feedback loop. Accountability would no longer depend on individual conscience; it would be embedded in infrastructure.

Information as the New Authority

Korea’s struggle is not only about medicine but about modern governance itself. The data age has eroded the notion that expertise can stand alone. In domains where information circulates faster than institutions can act, authority must be redefined as the capacity to decide responsibly within shared systems. The physician’s judgment remains central, but its legitimacy now depends on being verifiable, not untouchable.

If the past quarter-century of reform sought to separate profit from care, the next must separate discretion from impunity. Transparency must not humiliate expertise; it must discipline it. The question is no longer who may prescribe, but who may act on knowledge—and whether, in a system that sees everything, information itself can finally become a form of integrity.